Aptevo Therapeutics Reports Q2 2026 Financial Results

What Happened
Aptevo Therapeutics Inc. announced its financial results for the period ended June 30, 2026 via a press release dated August 14, 2026. The company furnished the press release as Exhibit 99.1 to an 8-K (Item 2.02) filed with the SEC; the information is furnished (not “filed”) and therefore not subject to certain liability provisions of the Securities Act.

Key Details

• Date filed: August 14, 2026 (8-K reporting Item 2.02: Results of Operations and Financial Condition).
• Reporting period: financial results for the period ended June 30, 2026.
• Exhibit: Press release attached as Exhibit 99.1 (furnished).
• Signature: Form signed by Daphne Taylor, Senior Vice President and Chief Financial Officer.

Why It Matters
The 8-K signals that Aptevo has released its latest quarterly operating and financial results; investors should review the attached press release for specific figures (revenue, net income/loss, cash position, and any management commentary or guidance). Note that because the release is furnished and not filed, it is not automatically incorporated by reference into future SEC filings unless explicitly stated. For investment decisions, watch for the company’s subsequent 10-Q or other filings that will formally report and reconcile quarterly financial statements.